Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of BIO-101 Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability (SARA-INT)

X
Trial Profile

Safety and Efficacy of BIO-101 Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability (SARA-INT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Muscular atrophy; Obesity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SARA INT
  • Sponsors Biophytis
  • Most Recent Events

    • 27 Mar 2023 According to a Biophytis media release, data from this study presented at the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR).
    • 27 Jun 2022 According to a Biophytis media release, results of this trial will be presented at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders).
    • 04 Oct 2021 According to a Biophytis media release, further analyses, e.g. on correlations between clinical endpoints and other parameters, biomarkers and actimetry are ongoing and will be communicated later in scientific congresses.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top